Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Noctura400 Treatment for Diabetic Retinopathy (CANDLE) (CANDLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02207712
Recruitment Status : Active, not recruiting
First Posted : August 4, 2014
Last Update Posted : March 4, 2020
Sponsor:
Information provided by (Responsible Party):
PolyPhotonix Medical

Tracking Information
First Submitted Date  ICMJE July 24, 2014
First Posted Date  ICMJE August 4, 2014
Last Update Posted Date March 4, 2020
Actual Study Start Date  ICMJE November 2014
Estimated Primary Completion Date July 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 5, 2016)
The number of intravitreal injections of ranibizumab required by each study eye at 48 weeks [ Time Frame: 48 Weeks ]
Original Primary Outcome Measures  ICMJE
 (submitted: July 31, 2014)
The mean difference between trial arms in the number of intravitreal injections of ranibizumab required by each study eye at 48 weeks [ Time Frame: 48 Weeks ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 5, 2016)
  • Mean difference from baseline Central sub-field thickness at 48 Weeks [ Time Frame: 48 Weeks ]
  • Mean difference from baseline visual acuity at 48 weeks. [ Time Frame: 48 Weeks ]
  • Mean difference in utility (quality of life). [ Time Frame: Baseline, 12 and 48 weeks ]
  • Difference in the number of ranibizumab injections received by patients who have received at least three injections. [ Time Frame: Between weeks 12 and 48 ]
  • Change in Central sub-field thickness over time [ Time Frame: 12, 24,36 and 48 Weeks ]
  • Pattern of injections given over the period of 48 weeks in both arms. [ Time Frame: 48 weeks ]
  • Adverse events rates [ Time Frame: 48 months ]
Original Secondary Outcome Measures  ICMJE
 (submitted: July 31, 2014)
  • Mean difference between treatment arms in change from baseline Central sub-field thickness at 48 Weeks [ Time Frame: 48 Weeks ]
  • Mean difference between treatment arms in change from baseline best corrected visual acuity at 48 weeks. [ Time Frame: 48 Weeks ]
  • Mean difference between treatment arms in utility (quality of life) as assessed by EQ-5D. [ Time Frame: Baseline, 12 and 48 weeks ]
  • Mean difference between treatment arms in the number of ranibizumab injections required [ Time Frame: Between weeks 12 and 48 ]
  • Change in Central sub-field thickness over time [ Time Frame: 12, 24,36 and 48 Weeks ]
  • Pattern of injections given over the period of 48 weeks in both arms. [ Time Frame: 48 weeks ]
  • Adverse events rates [ Time Frame: 48 months ]
Current Other Pre-specified Outcome Measures
 (submitted: October 5, 2016)
  • Compliance of wearing the mask [ Time Frame: 48 weeks ]
  • Changes in sleep pattern. [ Time Frame: 48 months ]
Original Other Pre-specified Outcome Measures
 (submitted: July 31, 2014)
  • Compliance of wearing the mask [ Time Frame: 48 weeks ]
  • Changes in sleep as assessed by the sleep questionnaires and diaries [ Time Frame: 48 months ]
 
Descriptive Information
Brief Title  ICMJE Noctura400 Treatment for Diabetic Retinopathy (CANDLE)
Official Title  ICMJE Noctura400 Treatment for Diabetic Retinopathy: Pilot Study to Demonstrate and Evaluate the Care Pathway for National Health Service (NHS) Adoption
Brief Summary

In this study, the investigators aim to use light masks (Noctura 400) to test the hypothesis that preventing the dark adaptation and associated hypoxia of the rods in the eye could in turn prevent or halt the progression of centre-involving Diabetic Macular Oedema (DMO). DMO is a devastating disease that is the most common cause of registerable blindness in the working age-group in the United Kingdom (UK)

This is a multi-centred randomised controlled trial involving 240 patients. Post randomization, participants in the intervention arm will wear the Noctura 400 Light Mask at night for 48 weeks in conjunction with their routine, prescribed treatment of intravitreal (eye) ranibizumab. Those in the standard arm will receive their routine, prescribed ranibizumab treatment only.

The primary objective is to determine whether utilizing the Noctura 400 Light Mask at night reduces the number of intravitreal injections of ranibizumab required by patients undergoing such a course for the treatment of DMO.

Detailed Description

Diabetes is regarded by the World Health Organisation (WHO) as a global epidemic, with the global diabetic population anticipated to exceed 500 million by 2020. In the UK there are over 3.5 million people who have diabetes with a growth rate exceeding 150,000 people per year. Diabetic Retinopathy (DR) is the most common complication of diabetes, and the most common cause of sight threatening retinopathy is Diabetic Macular Oedema (DMO).

This condition is characterised by leakage of fluid from compromised blood vessels in the central retina and 240,000 (8%) people with diabetes in the UK have clinically significant DMO, and 100,000 people with DMO have visual impairment. DMO is the most common cause of registerable blindness in the working age-group in the UK. The Diabetic Eye Screening Programme (DESP) annually photographs 3 million people with diabetes at a cost of £65 million to ensure early diagnosis of these sight threatening complications. All patients with diabetic maculopathy are referred to the Hospital Eye Service (HES).

Clinically significant macular oedema requires treatment. Non-central oedema is usually kept under close monitoring or laser treatment is advocated. Centre involving macular oedema is usually treated with intravitreal injections of inhibitors of Vascular Endothelial Growth Factor (anti-VEGF). Whilst laser treatment can reduce the risk of moderate visual loss by 50%, it is not effective in restoring best corrected visual acuity (BCVA) and has significant, quality of life impacting side effects. The anti-VEGF treatments are costly and cause significant burden to patients, their care-givers and the healthcare system.

A patient with DR never leaves the HES. With diabetes on the rise the cost of care for this ever increasing population is growing year on year. This is putting immense strain on the resources and budgets of the healthcare system.

In this trial the investigators will explore the health and economic impact of a new, novel therapy for DMO provided by the Noctura 400 Light Mask. The Light Mask provides a non-invasive, light therapy that can be administered at home by the patients themselves. If successful, the introduction of Noctura 400 Light Mask treatment could bring significant benefits to both patients and the healthcare system.

This trial has been designed as a randomised control trial to allow the direct assessment of the Noctura 400 treatment based on a comparison with a control arm of patients not receiving this treatment. All participants in the trial will be due to undergo their first year of a course of intravitreal injection of an anti-VEGF drug known as ranibizumab. Those in the treatment arm will, in addition to this course of injections, wear the Noctura 400 Light Mask each night for 48 weeks. Those in the standard, or control, arm will receive their course of injections only.

The study will involve 240 participants who have been diagnosed with clinically significant DMO and referred to the Hospital Eye Service (HES) for injections. The current threshold for referral is central retinal thickening of 400um or greater. Once in the HES, potential participants will be assessed for eligibility in clinic. These eligibility tests will form the future participant's "baseline visit". If eligible, patients will be invited to participate in the study. The eligibility assessment requires no further tests to those required by the routine care pathway.

After gaining informed consent, eligible and consenting participants will then be randomised into either the intervention arm (those wearing the Noctura 400 Light Mask each night in conjunction with their routine injections) or a standard arm (those receiving their injections only) and will then be invited back to clinic to begin their allocated therapy.

At the first trial visit, those in the intervention arm will be given the Noctura 400 Light Mask to take away with them and instructed how to use it. The Noctura 400 is powered and programmed to last for precisely 12 weeks. Participants will be provided with a replacement mask at appropriate appointments to ensure continuous treatment.

At each and every appointment all participants will undergo Optical Coherence Tomography (OCT) measurements (for assessment of disease progression) and visual acuity (VA) tests. For the first three visits all participants will be given intravitreal injections, following this, participants in both arms will be given injections at appointments only if required based on the results of the OCT and VA tests. Medical history, concomitant medications and adverse events will be recorded at each visit. At weeks 0,12 and 48 patients will fill out insomnia and sleepiness and quality of life questionnaires.

The Noctura 400 has the ability to sense and record when it has been used as a direct measure of compliance. Sleep Mask data will be collected at weeks 12,24,26 and 48. If compliance is low this will be discussed with the participant with the aim of increasing compliance. If at any point during the trial the Noctura 400 Light Mask appears faulty it will be returned for analysis and replaced.

The trial ends at the patient's last visit after 48 weeks of use. Participants will return their Noctura 400 Light Masks for analysis and then patients in both arms are free to continue their routine injections as prescribed by the current care pathway. Participants will be made aware at the time of consenting that the Noctura 400 Light Mask will not be available within the NHS at the end of the trial, but that the manufacturer intends for the device to be available to purchase privately

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Diabetic Macular Oedema
Intervention  ICMJE
  • Device: Noctura 400 Eye Mask
    The intervention is the wearing of the eye mask
    Other Name: Noctura400
  • Drug: Ranibizumab
    Standard ranibizumab treatment only
    Other Name: Those receiving their standard ranibizumab treatment only
Study Arms  ICMJE
  • Active Comparator: Standard Arm
    Those receiving only their prescribed ranibizumab treatment only
    Intervention: Drug: Ranibizumab
  • Experimental: Intervention Arm
    Noctura 400 Eye Mask in conjunction with their prescribed ranibizumab treatment.
    Interventions:
    • Device: Noctura 400 Eye Mask
    • Drug: Ranibizumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: February 16, 2018)
252
Original Estimated Enrollment  ICMJE
 (submitted: July 31, 2014)
240
Estimated Study Completion Date  ICMJE July 2020
Estimated Primary Completion Date July 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

i. Subjects of either sex aged 18 years or over. ii. Diagnosis of diabetes mellitus (type 1 or type 2). iii. Presence of clinically significant centre-involving macular oedema resultant from DR of ≥400µm (CST/CMT as measured by OCT, and is listed for ranibizumab therapy in the study eye.

Exclusion Criteria:

Any potential participant will be excluded if they have:

i. Received any previous anti-VEGF/steroid intravitreal injections in the study eye in the last 6 months.

ii. Presence of proliferative diabetic retinopathy (PDR) at screening.

iii. Significant systemic diseases know to affect visual function, other than diabetes (e.g. Parkinson's disease or Alzheimer's disease).

iv. History of relevant sleeping disorders/insomnia .

v. A condition that would preclude participation in the study.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 99 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02207712
Other Study ID Numbers  ICMJE PPX-2014-004
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party PolyPhotonix Medical
Study Sponsor  ICMJE PolyPhotonix Medical
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: Martin Holland PolyPhotonix Medical
Principal Investigator: Ulrich Meyer-Bothling Ashford & St Peters Hospitals NHS Trust
PRS Account PolyPhotonix Medical
Verification Date March 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP